Press releaseGlobe Newswire
Nexentis Technologies
NXTS · NASDAQ
$0.6153−$0.0251 (−3.92%)TodayMarket closed ·
Prev close $0.6404
Latest news
- Press releaseGlobe Newswire
Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
- Press releaseGlobe Newswire
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
- Press releaseGlobe Newswire
Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
- Press releaseGlobe Newswire
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
- Press releaseGlobe Newswire
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
- Press releaseGlobe Newswire
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
- NewsAvi Kapoor
Crude Oil Down Over 1%; US Manufacturing PMI Surges In June
- NewsAvi Kapoor
Dow Falls Over 300 Points; Korn Ferry Earnings Top Views
- NewsTanya Rawat
Nexentis Technologies Soars 156% Before Falling 46% After Hours — Here’s Why NXTS Stock Is Trending
- NewsAvi Kapoor
Crude Oil Falls Over 2%; Getty Images Shares Spike Higher
- NewsAvi Kapoor
Dow Jumps 200 Points; Outdoor Holding Shares Fall After Q4 Results
- Press releaseGlobe Newswire
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
- Press releaseGlobe Newswire
Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
- Press releaseGlobe Newswire
Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
- Press releaseGlobe Newswire
Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.